{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:45:09Z","timestamp":1788439509463,"version":"build-2803163510"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T00:00:00Z","timestamp":1735171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>The emergence of diverse resistance mechanisms after osimertinib therapy, including on-target epidermal growth factor receptor (EGFR) mutations and off-target alterations, warrants investigation of novel therapeutics to overcome these challenges and improve patient outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>COMPOSIT was a French, retrospective, multicenter, cohort study of the effectiveness and tolerability of osimertinib in combination with other targeted therapies in patients with advanced EGFR-mutant (EGFRm) non-small cell lung cancer (NSCLC) who harbored other oncogenic drivers as primary or acquired resistance mechanisms. Real-world progression-free survival (rwPFS), overall survival (OS), and objective response rate (ORR) were the primary endpoints.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The study included 61 patients (63.9% women; median age, 61 years). Chemotherapy was administered to 26 patients (42.6%) before the combinations. The most frequently targeted resistance mechanisms were MET amplification (n\u2005=\u200540) and BRAF alterations (n\u2005=\u200511). Sixteen combinations of osimertinib with other targeted therapies were reported. Overall (except for 10 patients in clinical trials), median rwPFS and OS were 3.9 (95% CI, 2.9-5.2) and 9.8 months (95% CI, 6.8-14.8). Best ORR (n\u2005=\u200554) was 50% (95% CI, 33.0-72.8). In patients with MET amplification (n\u2005=\u200529), median rwPFS and OS were 4.9 (95% CI, 2.9-7.2) and 8.6 months (95% CI, 5.3-21.6). Grade \u22653 adverse events occurred in 15 patients (24.6%). No deaths were related to treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Combinations of osimertinib with other targeted therapies appeared to be feasible and safe and may offer clinical benefit to overcome resistance to osimertinib in EGFRm NSCLC, especially in patients with MET amplification.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae312","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:12:12Z","timestamp":1730074332000},"source":"Crossref","is-referenced-by-count":6,"title":["COMPOSIT study: evaluating osimertinib combination with targeted therapies in <i>EGFR<\/i>-mutated non-small cell lung cancer"],"prefix":"10.1093","volume":"30","author":[{"given":"Camille","family":"Mehlman","sequence":"first","affiliation":[{"name":"Department of Pneumology and Thoracic Oncology, Tenon Hospital, Assistance Publique H\u00f4pitaux de Paris and GRC 4, Theranoscan, Sorbonne Universit\u00e9 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelie","family":"Swalduz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, L\u00e9on B\u00e9rard Cancer Centre , Lyon ,","place":["France"]},{"name":"Univ Lyon, Claude Bernard Lyon 1 University, INSERM 1052, CNRS 5286, Centre Leon B\u00e9rard, Cancer Research Center of Lyon , Lyon ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Monnet","sequence":"additional","affiliation":[{"name":"Department of Pneumology, Centre Hospitalier Inter-Communal de Creteil (CHIC) , Creteil ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Morin","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Centre Hospitalier Universitaire Larrey , Toulouse ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Wislez","sequence":"additional","affiliation":[{"name":"Unit\u00e9 d\u2019Oncologie Thoracique Service de Pneumologie Hopital Cochin, AP-HP Equipe \u201ccancer, immune control and escape\u201d Inserm U1138 Centre de Recherches des Cordeliers Universit\u00e9 Paris Cit\u00e9 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Guisier","sequence":"additional","affiliation":[{"name":"Normandie Univ, UNIROUEN, LITIS Lab QuantIF team EA4108, CHU Rouen, Department of Pneumology and Inserm CIC-CRB 1404 , F-76000 Rouen ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Curcio","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centre Francois Baclesse , Caen ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Du Rusquec","sequence":"additional","affiliation":[{"name":"Institut Curie, Institut du Thorax Curie-Montsouris , Paris-St Cloud,","place":["France"]},{"name":"Unit\u00e9 de Recherche INSERM U900, Universit\u00e9 Paris-Saclay , Saint-Cloud ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis B","family":"Cortot","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Department, Universit\u00e9 de Lille, CHU Lille, CNRS, INSERM, Institut Pasteur de Lille , UMR9020-UMR-S 1277-Canther , Lille ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Gounant","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, Thoracic Oncology Department, CIC INSERM 1425, Institut du Cancer AP-HP Nord, H\u00f4pital Bichat-Claude Bernard , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baptiste","family":"Abbar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Assistance Publique - H\u00f4pitaux de Paris (AP-HP), Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Institut Universitaire de Canc\u00e9rologie, INSERM U1135, CLIP\u00b2 Galil\u00e9e, Centre d\u2019Immunologie et des Maladies Infectieuses (CIMI-Paris) , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Duchemann","sequence":"additional","affiliation":[{"name":"Departement of Thoracic and Medical Oncology, Assistance Publique - H\u00f4pitaux de Paris (AP-HP), Avicenne, Bobigny ,","place":["France"]},{"name":"INSERM UMR1272 Hypoxie et poumon, Paris 13 - Universit\u00e9 Paris Nord , Bobigny ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Giroux-Leprieur","sequence":"additional","affiliation":[{"name":"Department of Respiratory Diseases and Thoracic Oncology, Universit\u00e9 Paris-Saclay, UVSQ, APHP-Hopital Ambroise Par\u00e9 , Boulogne-Billancourt ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Pierret","sequence":"additional","affiliation":[{"name":"Department of Pneumology, Hospices Civils of Lyon , Lyon ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fleur-Marie","family":"Quilot","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, University Hospital , Bourgogne-Franche Comt\u00e9 , Dijon ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Cadranel","sequence":"additional","affiliation":[{"name":"Department of Pneumology and Thoracic Oncology, Tenon Hospital, Assistance Publique H\u00f4pitaux de Paris and GRC 4, Theranoscan, Sorbonne Universit\u00e9 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5153-6951","authenticated-orcid":false,"given":"Vincent","family":"Fallet","sequence":"additional","affiliation":[{"name":"Department of Pneumology and Thoracic Oncology, Tenon Hospital, Assistance Publique H\u00f4pitaux de Paris and GRC 4, Theranoscan, Sorbonne Universit\u00e9 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,26]]},"reference":[{"key":"2025082905215741800_CIT0001","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/S0140-6736(16)00004-0","article-title":"Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)","volume":"387","author":"Barlesi","year":"2016","journal-title":"Lancet (London, England)"},{"key":"2025082905215741800_CIT0002","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"key":"2025082905215741800_CIT0003","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.annonc.2022.02.003","article-title":"ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer","volume":"33","author":"Passaro","year":"2022","journal-title":"Ann Oncol"},{"key":"2025082905215741800_CIT0004","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1200\/JCO.2016.70.3223","article-title":"Osimertinib in pretreated T790M-positive advanced non\u2013small-cell lung cancer: AURA study phase II extension component","volume":"35","author":"Yang","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025082905215741800_CIT0005","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1001\/jamaoncol.2018.2969","article-title":"Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib","volume":"4","author":"Oxnard","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025082905215741800_CIT0006","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br J Cancer"},{"key":"2025082905215741800_CIT0007","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.lungcan.2018.02.007","article-title":"Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib","volume":"118","author":"Wang","year":"2018","journal-title":"Lung Cancer"},{"key":"2025082905215741800_CIT0008","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/s41467-023-35961-y","article-title":"Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat Commun"},{"key":"2025082905215741800_CIT0009","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1158\/2159-8290.CD-18-1022","article-title":"Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion","volume":"8","author":"Piotrowska","year":"2018","journal-title":"Cancer Discov"},{"key":"2025082905215741800_CIT0010","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/po.18.00126","article-title":"Acquired ALK and RET gene fusions as mechanisms of resistance to osimertinib in EGFR -mutant lung cancers","volume":"1","author":"Offin","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"2025082905215741800_CIT0011","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1097\/JTO.0b013e31824fea45","article-title":"Secondary resistance to erlotinib: acquired T790M mutation and small-cell lung cancer transformation in the same patient","volume":"7","author":"Fallet","year":"2012","journal-title":"J Thorac Oncol"},{"key":"2025082905215741800_CIT0012","doi-asserted-by":"publisher","first-page":"105103","DOI":"10.18632\/oncotarget.21707","article-title":"Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors","volume":"8","author":"Baldacci","year":"2017","journal-title":"Oncotarget"},{"key":"2025082905215741800_CIT0013","doi-asserted-by":"publisher","first-page":"e232","DOI":"10.1016\/j.jtho.2018.07.012","article-title":"Combination of crizotinib and osimertinib or erlotinib might overcome MET-mediated resistance to EGFR tyrosine kinase inhibitor in EGFR-mutated adenocarcinoma","volume":"13","author":"Giroux-Leprieur","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2025082905215741800_CIT0014","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S1470-2045(19)30785-5","article-title":"Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study","volume":"21","author":"Sequist","year":"2020","journal-title":"Lancet Oncol"},{"key":"2025082905215741800_CIT0015","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2217\/fon-2021-1406","article-title":"INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance","volume":"18","author":"Smit E","year":"2022","journal-title":"Future Oncol"},{"key":"2025082905215741800_CIT0016","doi-asserted-by":"publisher","first-page":"S1419","DOI":"10.1016\/j.annonc.2022.08.054","article-title":"LBA52 Tepotinib + osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study [Abstract LBA52]","volume":"33","author":"Mazieres","year":"2022","journal-title":"Ann Oncol"},{"key":"2025082905215741800_CIT0017","doi-asserted-by":"publisher","first-page":"e226","DOI":"10.1016\/j.jtho.2019.05.046","article-title":"Response to the combination of osimertinib and trametinib in a patient with EGFR-mutant NSCLC harboring an acquired BRAF fusion","volume":"14","author":"Dagogo-Jack","year":"2019","journal-title":"J Thorac Oncol"},{"key":"2025082905215741800_CIT0018","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.lungcan.2020.05.036","article-title":"Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation","volume":"146","author":"Meng","year":"2020","journal-title":"Lung Cancer"},{"key":"2025082905215741800_CIT0019","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.lungcan.2019.10.014","article-title":"Response to the combination of dabrafenib, trametinib and osimertinib in a patient with EGFR-mutant NSCLC harboring an acquired BRAFV600E mutation","volume":"139","author":"Zhou","year":"2020","journal-title":"Lung Cancer"},{"key":"2025082905215741800_CIT0020","author":"National Cancer Institute","year":"2009"},{"key":"2025082905215741800_CIT0021","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1200\/JCO.2008.19.1635","article-title":"Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients","volume":"27","author":"Cappuzzo","year":"2009","journal-title":"J Clin Oncol"},{"key":"2025082905215741800_CIT0022","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.lungcan.2014.11.018","article-title":"Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing","volume":"87","author":"Jurmeister","year":"2015","journal-title":"Lung Cancer"},{"key":"2025082905215741800_CIT0023","doi-asserted-by":"publisher","first-page":"e601","DOI":"10.1016\/j.cllc.2020.05.015","article-title":"Combining EGFR and MET inhibition with crizotinib in EGFR-mutated lung adenocarcinoma harboring MET amplification: a brief report","volume":"21","author":"Aubanel","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"2025082905215741800_CIT0024","doi-asserted-by":"publisher","first-page":"722039","DOI":"10.3389\/fonc.2021.722039","article-title":"A large real-world study on the effectiveness of the combined inhibition of EGFR and MET in EGFR-mutant non-small-cell lung cancer after development of EGFR-TKI resistance","volume":"11","author":"Liu","year":"2021","journal-title":"Front Oncol"},{"key":"2025082905215741800_CIT0025","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/S2213-2600(20)30154-5","article-title":"Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b\/2, multicentre, randomised trial","volume":"8","author":"Wu","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2025082905215741800_CIT0026","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1158\/2159-8290.CD-22-0586","article-title":"Osimertinib + savolitinib to overcome acquired MET-mediated resistance in epidermal growth factor receptor-mutated, MET-amplified non-small cell lung cancer: TATTON","volume":"13","author":"Hartmaier","year":"2023","journal-title":"Cancer Discov"},{"key":"2025082905215741800_CIT0027","doi-asserted-by":"crossref","first-page":"S469","DOI":"10.1016\/j.jtho.2022.07.823","article-title":"EP08.02-140 MET biomarker-based preliminary efficacy analysis in SAVANNAH: savolitinib+osimertinib in EGFRm NSCLC post-osimertinib [Abstract EP08.02-140]","volume":"17","author":"Ahn","year":"2022","journal-title":"J Thorac Oncol"},{"key":"2025082905215741800_CIT0028","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"key":"2025082905215741800_CIT0029","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/S1470-2045(17)30679-4","article-title":"Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial","volume":"18","author":"Planchard","year":"2017","journal-title":"Lancet Oncol"},{"key":"2025082905215741800_CIT0030","doi-asserted-by":"publisher","first-page":"viii740","DOI":"10.1093\/annonc\/mdy424.063","article-title":"Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study [Abstract LBA50]","volume":"29","author":"Ramalingam","year":"2018","journal-title":"Ann Oncol"},{"key":"2025082905215741800_CIT0031","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.jtho.2017.08.006","article-title":"Combination osimertinib and gefitinib in C797S and T790M EGFR-mutated non\u2013small cell lung cancer","volume":"12","author":"Arulananda","year":"2017","journal-title":"J Thorac Oncol"},{"key":"2025082905215741800_CIT0032","first-page":"1723","article-title":"Lung adenocarcinoma harboring EGFR T790M and in trans C797S responds to combination therapy of first- and third-generation EGFR TKIs and shifts allelic configuration at resistance","volume":"12","author":"Wang","year":"2017","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"2025082905215741800_CIT0033","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1158\/1078-0432.CCR-15-0560","article-title":"The allelic context of the C797S mutation acquired upon treatment with third generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies","volume":"21","author":"Niederst","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2025082905215741800_CIT0034","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.cllc.2021.06.006","article-title":"Biomarker-directed phase II platform study in patients with EGFR sensitizing mutation-positive advanced\/metastatic non-small cell lung cancer whose disease has progressed on first-line osimertinib therapy (ORCHARD)","volume":"22","author":"Yu","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"2025082905215741800_CIT0035","doi-asserted-by":"publisher","first-page":"9507","DOI":"10.1200\/jco.2020.38.15_suppl.9507","article-title":"Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC). [Abstract 9507]","volume":"38","author":"Rotow","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025082905215741800_CIT0036","doi-asserted-by":"publisher","first-page":"14768","DOI":"10.1038\/ncomms14768","article-title":"Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer","volume":"8","author":"Uchibori","year":"2017","journal-title":"Nat Commun"},{"key":"2025082905215741800_CIT0037","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/nature17960","article-title":"Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors","volume":"534","author":"Jia","year":"2016","journal-title":"Nature"},{"key":"2025082905215741800_CIT0038","doi-asserted-by":"publisher","first-page":"5614","DOI":"10.1038\/s41467-022-33210-2","article-title":"Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors","volume":"13","author":"Kobayashi","year":"2022","journal-title":"Nat Commun"},{"key":"2025082905215741800_CIT0039","doi-asserted-by":"publisher","first-page":"e2200040","DOI":"10.1200\/PO.22.00040","article-title":"Durable response to combined osimertinib and pralsetinib treatment for osimertinib resistance due to novel intergenic ANK3-RET fusion in EGFR-mutated non-small-cell lung cancer","volume":"6","author":"Urbanska","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"2025082905215741800_CIT0040","doi-asserted-by":"publisher","first-page":"100343","DOI":"10.1016\/j.jtocrr.2022.100343","article-title":"Response to pralsetinib observed in meningeal-metastatic EGFR-mutant NSCLC with acquired RET fusion: a brief report","volume":"3","author":"Zhao","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"2025082905215741800_CIT0041","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1158\/1078-0432.ccr-22-2189","article-title":"Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers","volume":"29","author":"Rotow","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2025082905215741800_CIT0042","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1093\/annonc\/mdx404","article-title":"Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program","volume":"28","author":"Leduc","year":"2017","journal-title":"Ann Oncol"},{"key":"2025082905215741800_CIT0043","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1111\/cas.12996","article-title":"Not all epidermal growth factor receptor mutations in lung cancer are created equal: perspectives for individualized treatment strategy","volume":"107","author":"Kobayashi","year":"2016","journal-title":"Cancer Sci"},{"key":"2025082905215741800_CIT0044","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/nejmoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"key":"2025082905215741800_CIT0045","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"2025082905215741800_CIT0046","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1016\/j.jtho.2022.07.113","article-title":"MA07.03 real-world landscape of EGFR C797X mutation as a resistance mechanism to osimertinib in non-small cell lung cancer","volume":"17","author":"Ramalingam","year":"2022","journal-title":"J Thorac Oncol"},{"key":"2025082905215741800_CIT0047","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41392-022-01168-8","article-title":"Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective","volume":"7","author":"Yang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"2025082905215741800_CIT0048","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/8\/oyae312\/61280902\/oyae312.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/8\/oyae312\/61280902\/oyae312.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T09:22:05Z","timestamp":1756459325000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyae312\/7933219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,26]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae312","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2024,12,26]]},"article-number":"oyae312"}}